Show simple item record

dc.contributor.authorBernal, Juan Antonio 
dc.date.accessioned2019-06-13T07:20:16Z
dc.date.available2019-06-13T07:20:16Z
dc.date.issued2013-12
dc.identifier.citationJ Cardiovasc Transl Res. 2013; 6(6):956-68es_ES
dc.identifier.issn1937-5387es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7771
dc.description.abstractThe therapeutic potential of induced pluripotent stem cells (iPSCs) is well established. Safety concerns remain, however, and these have driven considerable efforts aimed at avoiding host genome alteration during the reprogramming process. At present, the tools used to generate human iPSCs include (1) DNA-based integrative and non-integrative methods and (2) DNA-free reprogramming technologies, including RNA-based approaches. Because of their combined efficiency and safety characteristics, RNA-based methods have emerged as the most promising tool for future iPSC-based regenerative medicine applications. Here, I will discuss novel recent advances in reprogramming technology, especially those utilizing the Sendai virus (SeV) and synthetic modified mRNA. In the future, these technologies may find utility in iPSC reprogramming for cellular lineage-conversion, and its subsequent use in cell-based therapies.es_ES
dc.description.sponsorshipThis work was supported by a grant (BFU2012-35258) to J.A. Bernal from the Ministry of Economy and Competitivity. J.A. Bernal was also supported by the Spanish Ramón y Cajal program (RYC2009-04341) from the Ministry of Science and Innovation.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshCell Differentiation es_ES
dc.subject.meshCell Lineage es_ES
dc.subject.meshCellular Reprogramming es_ES
dc.subject.meshEpigenesis, Genetices_ES
dc.subject.meshGene Expression Regulation, Developmental es_ES
dc.subject.meshGenetic Vectors es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInduced Pluripotent Stem Cells es_ES
dc.subject.meshMicroRNAs es_ES
dc.subject.meshRNA es_ES
dc.subject.meshRNA, Messenger es_ES
dc.subject.meshSendai virus es_ES
dc.subject.meshTranscription Factors es_ES
dc.subject.meshGene Transfer Techniques es_ES
dc.titleRNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applicationses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID23852582es_ES
dc.format.volume6es_ES
dc.format.number6es_ES
dc.format.page956-68es_ES
dc.identifier.doi10.1007/s12265-013-9494-8es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.description.peerreviewedes_ES
dc.identifier.e-issn1937-5395es_ES
dc.relation.publisherversionhttps://doi.org/10.1007/s12265-013-9494-8es_ES
dc.identifier.journalJournal of cardiovascular translational researches_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Cardiomiopatías de origen genéticoes_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BFU2012-35258es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RYC2009-04341es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional